Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Apartment Investment and Management Co (AIV) vs Merck & Co., Inc. (MRK) Price & Performance

Apartment Investment and Management CoTrade
Merck & Co., Inc.Trade

Price performance (Past 24H)

Key statistics

Apartment Investment and Management Co vs Merck & Co., Inc. — how do they compare? Apartment Investment and Management Co trades at $2.61 (market cap $376.16M), while Merck & Co., Inc. trades at $131.82 (market cap $321.77B). The key difference: Merck & Co., Inc. is far larger — about 855.4× Apartment Investment and Management Co's market cap, and Merck & Co., Inc. pays a 2.61% dividend while Apartment Investment and Management Co pays none. Which is the better fit depends on your goals.

AIVMRK
Market Cap
$376.16M$321.77B
Sector
Real EstateHealth
52-Week High
$7.93$131.84
52-Week Low
$2.59$77.60
Enterprise Value
$738.32M$368.53B
Dividend Yield
2.61%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Apartment Investment and Management Co

AIV trades at $2.62, down 1.5% recently, with a bearish technical signal from moving averages. The company reported Q4 2025 EPS of $1.06, beating expectations, but revenue declined to $138.49M in 2025. Valuation ratios show a low P/B of 0.76, suggesting potential undervaluation, while a net income margin of 400.05% reflects significant one-time tax benefits. Cash flow improved with a net inflow of $234M in 2025.

Outlook is mixed: strong profitability metrics and a scheduled dividend in 2026 offer upside, but inconsistent earnings history and revenue volatility pose risks. Analyst consensus is cautious with 33% buy ratings. Investors should weigh the attractive valuation against operational challenges in the real estate sector.

Merck & Co., Inc.

Merck (MRK) trades at $130.9, up 1.81% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $140.36. Recent earnings beats and a 72.97% gross margin highlight strong profitability, while the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline. The stock faces headwinds from a high P/E ratio of 104.34 and fluctuating cash flows.

The outlook is positive with robust fundamentals and strategic M&A, but valuation concerns and competitive pressures in pharma pose risks. Upside is likely if earnings growth continues, though investors should monitor debt levels and integration of acquisitions.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Apartment Investment and Management Co

Apartment Investment & Management Co is a self-managed real estate investment trust. It is focused on property development, redevelopment and various other value-creating investment strategies, targeting the U.S multifamily market. Its operating segments are Development and Redevelopment

Read more on AIV

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.

Read more on MRK